| Name | Title | Contact Details |
|---|
At Olympus, we put a lot of good back into the world, and what we do, really matters. We are committed to making people`s lives healthier, safer and more fulfilling every day by crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products. Everything we do at Olympus is a reflection of our vision, and everyone here helps to make it a reality. We view our relationship with and commitment to our employees with the same passion. Everything we do at Olympus is a reflection of our purpose and everyone here helps to make it a reality. We`re invested in our employees, great ideas, and how they impact the communities around us. We see the world through multiple lenses and come together to find the right answers; the best solutions. Olympus Corporation of the Americas (OCA)—a wholly owned subsidiary of Olympus Corporation in Tokyo, Japan—is headquartered in Center Valley, Pennsylvania, and employs more than 5,300 people at our locations throughout North and South America. Join us!
Transfer Master Products Inc is a Postville, IA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Opto IQ is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Litigation is a Lancaster, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.